CRISPR-Based Diagnostics Market Global Report 2026

The crispr-based diagnostics market size has grown rapidly in recent years. It will grow from $3.71 billion in 2025 to $4.32 billion in 2026 at a compound annual growth rate (CAGR) of 16.5%. The growth in the historic period can be attributed to the need for rapid and accurate diagnostics, limitations of traditional molecular tests, pandemic-driven demand for diagnostics, advancements in CRISPR detection methods, and academic validation of CRISPR diagnostics.

The crispr-based diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.83 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to the expansion of decentralized testing approaches, rising demand for early disease detection, increasing adoption of point-of-care diagnostic solutions, growing integration with digital health platforms, and wider use in oncology and genetic screening applications. Major trends in the forecast period include increasing adoption of rapid molecular diagnostic technologies, expansion of point-of-care testing solutions, growing use for infectious disease detection, greater integration of isothermal amplification technologies, and expansion of personalized diagnostic applications.

The growing incidence of infectious diseases is anticipated to support the expansion of the CRISPR-based diagnostics market in the forecast period. Infectious diseases are medical conditions caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which may be transmitted directly or indirectly between individuals through contaminated surfaces, food, water, or vectors such as insects. The incidence of infectious diseases is increasing because of globalization, antimicrobial resistance, climate change, urbanization, population growth, habitat destruction, and limited access to healthcare services. CRISPR-based diagnostics support the detection and management of infectious diseases by enabling rapid and precise identification of pathogens, supporting early diagnosis, prompt treatment, and effective disease containment. For instance, in August 2024, according to data published by the UK Health Security Agency, a UK-based executive agency, England recorded 368 measles cases in 2023, representing an almost sevenfold increase compared with the 53 cases reported in 2022, while the West Midlands and London accounted for 44% and 33% of the cases, respectively. Therefore, the increasing incidence of infectious diseases is contributing to the growth of the CRISPR-based diagnostics market.

Leading companies operating in the CRISPR-based diagnostics market are focusing on developing strategic partnerships to enhance accessibility to rapid and accurate diagnostics through CRISPR-based point-of-care tests. A strategic partnership is a long-term collaboration between two or more organizations that share resources and expertise to achieve mutual goals and strengthen their competitive advantage. For example, in August 2023, CrisprBits Private Limited, an India-based biotechnology company, announced a strategic collaboration with Molbio Diagnostics, an India-based molecular diagnostics company, to develop CRISPR-based Point-of-Care Tests (POCTs). This collaboration focuses on creating rapid, precise, and cost-effective diagnostic tools leveraging CRISPR technology for detecting pathogens and genetic markers. These POCTs aim to enhance diagnostic accessibility in diverse settings, including resource-limited areas, while ensuring swift and accurate disease detection. The partnership combines CrisprBits' expertise in CRISPR-based platforms with Molbio's manufacturing and distribution capabilities to bring these tests to the global market.

In February 2024, Ginkgo Bioworks Holdings Inc., a US-based biotechnology company, acquired Proof Diagnostics Inc. for an undisclosed amount. Through this acquisition, Ginkgo aimed to strengthen its gene therapy services by incorporating Proof Diagnostics’ OMEGA RNA-programmable nuclease technology and advancing its gene editing capabilities. The acquisition enhances Ginkgo’s ability to provide sophisticated solutions for therapeutic development and precision gene editing. Proof Diagnostics Inc. is a US-based biotechnology company that develops advanced CRISPR-based molecular testing solutions for COVID-19.

Major companies operating in the crispr-based diagnostics market are Thermo Fisher Scientific Inc., Integrated DNA Technologies Inc., Molbio Diagnostics, Horizon Discovery, Synthego Corporation, Caribou Biosciences, Mammoth Biosciences, Epic Bio, VedaBio, CrisprBits, SNIPR BIOME ApS, TOLO Biotech, Intact Genomics, Agdia Inc., ToolGen Inc., Caspr Biotech, GenScript, Twist Bioscience, Revvity Discovery Limited, Danaher Corporation, Scope Biosciences, CRISPR Diagnostics, Gene Editing Institute, Aptitude Medical Systems, Qiagen, Abingdon Health.

North America was the largest region in the CRISPR-based diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr-based diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the crispr-based diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CRISPR-based diagnostics market includes revenues earned by entities by providing services such as diagnostic testing services, custom CRISPR assays development, screening and surveillance services, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR-based diagnostics market also consists of sales of CRISPR-based RNA detection systems, CRISPR-based monitoring tools, lateral flow assays, and CRISPR-based test platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

This product will be delivered within 1-3 business days.